Connect with us

Science

How Iran Accumulated 11 Tons of Enriched Uranium

Published

on

How Iran Accumulated 11 Tons of Enriched Uranium

Since eight years ago when President Trump pulled out of a nuclear deal with Tehran, Iran has accumulated 22,000 pounds, or 11 tons, of enriched uranium. But the fate of Iran’s stockpile remains a mystery, two months after the United States began a war meant to prevent Iran from ever building an atomic bomb.

Uranium can light cities or destroy them. Low concentrations can power nuclear reactors. Higher concentrations, from a process called enrichment, can make nuclear bombs.

Advertisement

Concentrations in Iran’s stockpile

Advertisement

Uranium enrichment gets increasingly easy and fast as concentrations rise. It’s much harder to get to 20 percent from 0 percent than to 60 percent from 20 percent, or even to 90 percent — the preferred level for making nuclear arms.

Advertisement
Advertisement

Iran began enriching uranium on an industrial scale in 2006, describing its aims as peaceful. Reports from the International Atomic Energy Agency showed the stockpile growing over the next few years.

Chart shows the increasing stockpile of uranium enriched up to 5 percent, in light purple, from 2008 to 2010.

In 2010, Iran said it would begin enriching uranium up to 20 percent — ostensibly to make fuel for a research reactor. This level is the official dividing line between civilian and military uses.

Advertisement

Chart shows the increasing stockpile of uranium enriched up to 5 percent, in light purple, from 2008 to 2013, when it reaches about 20,000 pounds. A new area on the chart, in medium purple and indicating 20 percent enrichment, grows from 2010 onward.

The 20 percent level was alarming because it was about 80 percent of the way to bomb-grade fuel.

Advertisement

Chart zooms in into the area of uranium enriched to 20 percent.

As the stockpile kept growing, the Obama administration began talks to curb it.

In 2015, Iran and six nations led by the United States reached an accord that limited the purity of its enriched uranium to 3.67 percent and the size of its stockpile for 15 years.

Advertisement

Chart extends to show the increasing stockpile of uranium enriched to 5 percent, in light purple, from 2008 to 2015. The area of enriched to 20 percent is visible from 2010 to 2014.

Under the deal, Tehran shipped 25,000 pounds of enriched uranium, or 12.5 tons, and restricted the size of its stockpile to under 660 pounds.

Advertisement

Chart extends to show the stockpile of uranium enriched up to 2018, with the limit on its size imposed by the 2015 deal marked with a red line. The chart also shows a huge drop in the levels of enriched uranium after 2016.

Iran lacked a single bomb’s worth of uranium in 2018, when Mr. Trump withdrew the United States from the pact and reimposed a series of tough economic sanctions.

Then Iran began to enrich above the deal’s limit, first at low enrichment levels to pressure the West and then up to 20 percent in early 2021, just before Mr. Trump left office.

Advertisement

Chart shows the stockpile of uranium enriched from 2016 to 2022, and highlights May 2018, when Trump revoked the Iran nuclear deal.

The Biden administration tried, unsuccessfully, to restore aspects of the abandoned deal. Throughout the negotiations, Iran enriched uranium to an unprecedented level of up to 60 percent — a hairsbreadth away from the preferred grade for atom bombs.

Advertisement

Chart shows the stockpile of uranium enriched from 2019 to 2025, with all levels of enrichment increasing. Enrichment to 60 percent is also visible in dark colors from 2021 to 2025.

With Mr. Trump again in office in 2025, Iran’s stockpile of enriched uranium grew at the fastest rate since the International Atomic Energy Agency started reporting.

Chart zooms out to see the entire extent of the timeline, from 2006 to 2025.

Advertisement

In June 2025, during the 12-day war, the United States bombed Iran’s enrichment plants at Natanz and Fordow, as well as its uranium storage tunnels at Isfahan. One month later, Iran suspended cooperation with the I.A.E.A., ending the monitoring of the nation’s enrichment sites.

In the absence of on-site inspections and despite satellite monitoring, the location of the 11-ton stockpile remains uncertain.

Advertisement

Radioactive and chemically hazardous, parts of the stockpile remain hidden or buried under wartime rubble, making them difficult targets to access or destroy. It’s even a challenge to confirm they exist.

Even if Iran were to dig out the uranium, experts said, it would take many months — perhaps more than a year — to turn it into a warhead. They added that Iran, when the war started, posed no imminent nuclear threat.

The Trump administration has argued that U.S. satellites are monitoring the deeply buried uranium and that the cache is of little or no use to Iran because of the wide destruction of its nuclear sites and know-how.

Advertisement

Analysts question these assertions. They say Iran last year may have set up an enrichment plant in the mountain tunnels that adjoin its Isfahan site, where Tehran is also seen as storing the bulk of its uranium stockpile. If so, they say, that raises the possibility that Iran has a covert site where it might conduct new rounds of fuel enrichment to make fuel for an atomic bomb.

Advertisement

Methodology

Advertisement

To extract enrichment figures, The New York Times reviewed reports published quarterly by the International Atomic Energy Agency from 2003 to 2025. The agency started to report enrichment figures in February 2008. In 2016, it reported that the stockpile did not exceed 300 kilograms, or 660 pounds, of 3.67 percent enriched uranium, without providing exact figures.

Science

Infant formula recalled after California baby sickened with botulism

Published

on

Infant formula recalled after California baby sickened with botulism

Nara Organics recalled its whole milk baby formula after a California child and two others were sickened by potentially fatal infant botulism, federal officials said.

Parents should immediately stop giving the formula to their children, said officials from the U.S. Centers for Disease Control and Prevention. Unopened cans should be returned or thrown away.

All three infants, who ranged in age from 2 to 5 months, were hospitalized and given a drug to treat infant botulism, officials said. No deaths have been reported.

Parents should quickly seek medical care for an infant who has difficulty swallowing, poor feeding, loss of head control or decreased facial expression, the CDC said. Other symptoms include constipation, drooping eyelids, sluggish pupils and a weak cry.

Advertisement

Because symptoms of infant botulism can take several weeks to begin, officials said, parents of children who have consumed the formula should monitor their child for signs for a month after the product was last consumed.

Nara Organics formula is sold online and at Target stores. The two other infants who were hospitalized were from Pennsylvania and Washington.

The New York company said in a statement that so far its product had not tested positive for the bacterium Clostridium botulinum. Nevertheless, the company said, it decided to recall all products currently on the market.

“We sincerely apologize for the concern and distress this announcement causes our customers,” the company said. “We are committed to leading with transparency and accountability throughout this process as we work to identify further information.”

Consumers can find refund information on the company’s website at nara.com.

Advertisement

Infant botulism happens when swallowed spores from the bacterium infect a baby’s large intestine and make a toxin in it. If not treated, the child can experience a progressive paralysis that can lead to breathing difficulties and require weeks of hospitalization.

Last year, another manufacturer recalled its product — ByHeart Whole Nutrition Infant Formula — after an outbreak of infant botulism sickened dozens of babies across the country.

Continue Reading

Science

What COVID is teaching doctors about the relationship between viruses and cancer

Published

on

What COVID is teaching doctors about the relationship between viruses and cancer

In early 2022, around the time the Omicron variant started driving a new surge in COVID-19 cases, researchers at James DeGregori’s University of Colorado Anschutz lab noticed something unusual: When lab mice with dormant breast cancer cells were infected with either influenza or SARS-CoV-2, the animals were significantly more likely to develop aggressive lung tumors.

What’s true for a mouse isn’t always true for a human. But when the team examined healthcare databases, they were surprised to find that something similar appeared to be going on in the human population.

Analysis of records from the U.K. Biobank showed that cancer survivors who contracted COVID in 2020 — when the virus was new and no vaccine was available — were significantly more likely to die of recurring cancer than patients who didn’t get the virus, particularly within the year after their COVID infection.

Analysis of a separate U.S. breast cancer database found that breast cancer patients in remission who got COVID were significantly more likely to develop metastatic lung tumors than patients who did not contract the virus.

Advertisement

The University of Colorado researchers couldn’t analyze influenza’s effects as thoroughly — most flu infections don’t make it into medical charts, as patients often ride out routine cases at home. They also weren’t able to take into account whether the severity of a patient’s COVID infection influenced the likelihood of a cancer recurrence. But COVID’s novelty gave the team the data it needed to track the effects of viral inflammation on cancer recurrence. Their results were published last year in the journal Nature.

“When [cancer] comes back, it comes back with a fury,” DeGregori said. “We think that these virus infections can be almost like fuel for the fire.”

Unwelcome as COVID’s emergence was, the sheer scale of its spread has vastly deepened science’s understanding of the ways that viruses can continue to affect a human body long after the initial illness has passed.

Scientists need a critical mass of data to be able to identify statistically significant patterns. In the case of a global pandemic “where the whole population gets infected, basically you have a denominator of 7 billion people,” said Dr. Stanley Perlman, a University of Iowa microbiologist who studies coronaviruses.

The rapid increase in patients suffering from long COVID supercharged research on post-viral syndromes — the complex collection of lingering symptoms doctors have long observed in some patients infected with pneumonia, flu or other viruses.

Advertisement

Now, as more years of post-pandemic data have accumulated, scientists are also able to look more closely at the complicated relationship between COVID and cancer, a disease that takes significantly longer to make itself known.

“This is something that merits more attention,” said Dr. Aditya Bardia, director of Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center. Bardia’s lab has also observed associations between COVID infection and breast cancer recurrence; that research has not yet been submitted for peer review.

There isn’t sufficient evidence to indicate that COVID is an oncogenic, or cancer-causing, virus, a half-dozen researchers contacted for this article said. The virus has some significant structural differences from known oncogenic viruses such as human papilloma virus, which is linked to cervical cancer, and hepatitis B and C, which are associated with liver cancer.

But the pandemic has left some evidence that viral infection may play a role in reawakening dormant cancer cells present in a patient’s body before infection.

“COVID and influenza do not cause cancer under themselves, but if you have cancer and you have dormant cancer cells that are normally under control by your immune system, getting a severe case of COVID can help reactivate those existing cancers,” said Dr. Patrick Moore, a virologist and epidemiologist at the University of Pittsburgh.

Advertisement

A sharp increase in metastatic breast cancer cases in the pandemic’s early years was largely attributed to care delayed by pandemic restrictions, rather than a real increase in incidence.

More recent work suggests that “it’s not just the logistics of the pandemic, but it’s really something inherent to infection” behind the association with cancer recurrence, said Melanie Ott, director of the Gladstone Institute of Virology and a professor of medicine at UC San Francisco.

The effect isn’t specific to COVID, as DeGregori’s Nature paper shows, Ott pointed out. One of the body’s natural defense mechanisms against a virus like COVID or influenza is the release of cytokines, proteins that act as chemical messengers helping to coordinate the immune system’s response.

But in some cases of severe infection, the immune system can overcorrect and send out an excess amount of these proteins, a serious and potentially fatal reaction called a cytokine storm.

Research in the early months of the pandemic showed that patients with severe COVID who died or required hospitalization were much more likely to have runaway levels of cytokines, including a particular protein called interleukin-6, or IL-6.

Advertisement

Chronically high IL-6 levels have also been linked to recurrence and metastasis of multiple types of cancer.

DeGregori’s team found that breast cancer cells in mice whose dormant cancers returned after a COVID infection reactivated in response to high levels of IL-6. Their research couldn’t prove that the same biological process happens in humans, DeGregori said. But the fact that a review of real-life patient data showed a high correlation between COVID infection and cancer recurrence makes him think they are on to something.

It’s not a settled question, even among the paper’s authors. Dr. Doug Wallace, director of the Center for Mitochondrial and Epigenomic Medicine at Children’s Hospital of Philadelphia and a co-author on the Nature paper, said he has a “slightly different interpretation” of the data.

IL-6 also inhibits mitochondria, the parts of a cell that generate energy. Wallace thinks that this suppression of the cells’ powerhouses is actually what’s encouraging cancer growth. (Mitochondrial dysfunction is also a prime suspect in the cause of long COVID.)

Other viruses shut down mitochondrial function too, Wallace said. SARS-CoV-2 seems to be particularly good at it, which could be the reason an infection leads to the lingering misery of long COVID in some people or an unexpected recurrence of cancer in others.

Advertisement

Researchers stressed that this area of study is still in its early days, and there is no definitive causal link between COVID infection and cancer recurrence.

“It’s fair to say that [COVID infection] could be added to the long list of theoretical reasons that cancer might be more likely to come back, [but] I’m on the skeptical side of all things. Prove it to me,” said Dr. Eric Winer, director of the Yale Cancer Center. “This is one where I’d say, interesting finding, let’s look more.”

The evidence to date suggests simply that the question is worthy of more study, researchers said. If there is any action people with vulnerable immune systems should take as a result, it’s to continue reasonable precautions against viral infections of all kinds.

“There’s a very, very, very compelling reason for those patients who have chronic diseases to avoid getting a severe case of influenza or COVID or respiratory syncytial [virus] — all of these diseases for which good, safe, effective vaccines exist,” Moore said.

Advertisement
Continue Reading

Science

Oliver Tree, musician and Santa Cruz native, dies in helicopter crash

Published

on

Oliver Tree, musician and Santa Cruz native, dies in helicopter crash

Oliver Tree, a genre-defying singer-songwriter and Santa Cruz native, was one of six people killed when two helicopters collided Sunday morning in Brazil, according to the Associated Press. He was 32.

Tree, a quirky artist known for his highly theatrical music videos and crisp bowl cut, had been traveling through South America as a part of his world tour. CNN Brazil reported Argentinian YouTuber Gaspar Prim, also known as Gaspi, was among those killed in the crash.

The mid-air collision occurred in Rio de Janeiro, with one of the helicopters landing in the parking lot of a car dealership, the AP reports. Local authorities have launched an investigation into the cause of the crash.

Tree, born Oliver Tree Nickell, broke out in the electronic music world first performing as, simply, Tree. He released an e.p., “Demons,” in 2013, which included a cover of Radiohead’s “Karma Police” that caught the ear of Thom Yorke. He later attended CalArts north of Los Angeles, and signed to Atlantic Records for his major-label debut e.p. “Alien Boy” in 2018.

Advertisement

To find his distinct look, he told the Santa Cruz Sentinel that “I was making a statement with it. Everybody’s trying to look so beautiful and sexy nowadays. It was my way of rebelling against that. So, I tried to make myself look as silly and ridiculous as possible.”

Tree was an instant hit on the festival circuit for his outlandish stage productions and outsider charisma, performing at Lollapalooza, Coachella and Outside Lands. He collaborated with Skrillex, David Guetta and Zeds Dead, and was fiercely protective of his meticulously weird visual identity and video concepts, telling Rolling Stone that “That’s kind of my signature. The people who do f- with me know me because of my videos..Music is my day job but my real dream is to be making feature films.

He released his major label debut LP, “Ugly Is Beautiful,” in 2020. His hit song “Life Goes On” and collaboration “Miss You” with German DJ Robin Schulz earned him international recognition and climbed onto the Billboard Hot 100. He released four full length albums as Oliver Tree, most recently April’s independent LP “Love You Madly Hate You Badly.”

Tree had performed in Buenos Aires on June 4.

From July to October, he had shows scheduled throughout Europe, Australia and China. This year, he performed at the Coachella Valley Music and Arts Festival this year as a special guest of electronic producer Subtronics. In one of his last social media posts, he made a point to spotlight an upcoming show on Aug. 9 in his hometown at the Quarry Amphitheater at UC Santa Cruz.

Advertisement

“I can’t believe Oliver is gone,” Schulz posted on Instagram. “You were such a lovely soul and a one of a kind character. Working with you on ‘Miss You’ was an honor. My deepest condolences to his family, friends and everyone who loved him.”

Continue Reading
Advertisement

Trending